Strategies for implementing lipid-lowering therapy: Pharmacy-based approach

American Journal of Cardiology

Volumn 85, Issue 3 SUPPL. 1, 2000, Pages 30-35

  Birtcher, Kim K ^a   Bowden, Carol ^a   Ballantyne, Christie M ^a,b   Huyen, Michelle ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DECISION MAKING; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTILIPEMIC AGENTS; HOSPITALS, TEACHING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; MANAGED CARE PROGRAMS; MYOCARDIAL INFARCTION; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033964698     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00936-4     Document Type: Article

References (7)

1. Grundy S.M., Balady G.J., Criqui M.H., Fletcher G., Greenland P., Hiratzka L.F., Houston-Miller N., Kris-Etherton P., Krumholz H.M., LaRosa J. When to start cholesterol-lowering therapy in patients with coronary heart disease a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction . Circulation. 95:1997;1683-1685.
2. Ryan T.J., Anderson J.L., Antman E.M., Braniff B.A., Brooks N.H., Califf R.M., Hillis L.D., Hiratzka L.F., Rapaport E., Reigel B.J., et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) . J Am Coll Cardiol. 28:1996;1328-1428.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
4. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L.E., Warnica J.W., Arnold J.M.O., Wun C.-C., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
6. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
7. McBride P., Schrott H., Plane M.B., Underbakke G., Brown R.L. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med. 158:1998;1238-1244.